ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 658,35
0,26%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. PTC Therapeutics Inc (PTCT)

  7. PTC Therapeutics Inc (PTCT) Actualités

PTCT

PTC Therapeutics (PTCT)

PTC Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTCT
DateHeureSourceTitreSymboleSociété
29/05/202414h00PR Newswire (US)PTC Therapeutics to Participate at Upcoming Investor ConferenceNASDAQ:PTCTPTC Therapeutics Inc
28/05/202414h30PR Newswire (US)PTC Therapeutics Announces Validation of Sepiapterin European MAANASDAQ:PTCTPTC Therapeutics Inc
24/05/202423h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PTCTPTC Therapeutics Inc
22/05/202416h12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PTCTPTC Therapeutics Inc
20/05/202418h20PR Newswire (US)PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluationNASDAQ:PTCTPTC Therapeutics Inc
20/05/202413h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PTCTPTC Therapeutics Inc
14/05/202413h30PR Newswire (US)PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™NASDAQ:PTCTPTC Therapeutics Inc
02/05/202414h00PR Newswire (US)PTC Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:PTCTPTC Therapeutics Inc
25/04/202422h05PR Newswire (US)PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
23/04/202422h30PR Newswire (US)PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PTCTPTC Therapeutics Inc
11/04/202414h00PR Newswire (US)PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
28/03/202413h30PR Newswire (US)PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMANASDAQ:PTCTPTC Therapeutics Inc
19/03/202412h30PR Newswire (US)PTC Therapeutics Provides Key Regulatory UpdatesNASDAQ:PTCTPTC Therapeutics Inc
29/02/202422h05PR Newswire (US)PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
15/02/202414h00PR Newswire (US)PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
14/02/202421h50Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PTCTPTC Therapeutics Inc
14/02/202413h13Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PTCTPTC Therapeutics Inc
25/01/202422h05PR Newswire (US)CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination ProcedureNASDAQ:PTCTPTC Therapeutics Inc
08/01/202415h26PR Newswire (US)PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PTCTPTC Therapeutics Inc
03/01/202414h00PR Newswire (US)PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PTCTPTC Therapeutics Inc
05/12/202323h24Dow Jones NewsPTC Therapeutics Gives Updates on Translarna Regulatory ActivitiesNASDAQ:PTCTPTC Therapeutics Inc
05/12/202322h15PR Newswire (US)PTC Therapeutics Provides Updates on Translarna™ Regulatory ActivitiesNASDAQ:PTCTPTC Therapeutics Inc
07/11/202322h16Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:PTCTPTC Therapeutics Inc
26/10/202322h34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PTCTPTC Therapeutics Inc
26/10/202322h05PR Newswire (US)PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
19/10/202314h00PR Newswire (US)PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 BillionNASDAQ:PTCTPTC Therapeutics Inc
16/10/202322h30PR Newswire (US)PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results NASDAQ:PTCTPTC Therapeutics Inc
29/09/202313h29IH Market NewsFriday’s Wall Street Highlights: New Integrated, Nike, Tesla, Alphabet, and moreNASDAQ:PTCTPTC Therapeutics Inc
29/09/202302h12Dow Jones NewsStocks to Watch: Nike, Novo Integrated, PTC TherapeuticsNASDAQ:PTCTPTC Therapeutics Inc
28/09/202322h30PR Newswire (US)PTC Announces Further Strategic Prioritization and Associated Reduction in WorkforceNASDAQ:PTCTPTC Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PTCT

Dernières Valeurs Consultées

EU
MC
Lvmh Moet Hennessy Louis...
NYSE
JPM
JP Morgan Chase
COIN
BTCUSD
Bitcoin
EU
BEL20
Bel 20
EU
RI
Pernod Ricard
EU
BNP
BNP Paribas
EU
LR
Legrand
EU
SGO
Cie de SaintGobain
EU
CAP
Capgemini
NYSE
MCD
McDonalds
EU
VK
Vallourec
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés